| Animal Disease Risk Assessment,
Prevention, and Control Act of 2001 (Introduced in the Senate)
S 708 IS
107th CONGRESS
1st Session
S. 708
To provide the citizens
of the United States and Congress with a report on coordinated actions
by Federal agencies to prevent the introduction of foot and mouth disease
and bovine spongiform encephalopathy into the United States and other information
to assess the economic and public health impacts associated with the potential
threats presented by those diseases.
IN THE SENATE OF THE UNITED
STATES
April 5, 2001
Mr. HATCH (for himself, Mr.
HARKIN, Mr. CAMPBELL, Mr. DURBIN, Mr. DASCHLE, Mr. ROBERTS, Mr. DAYTON,
Mr. CONRAD, Mr. DORGAN, Mr. JOHNSON, Mr. FEINGOLD, Mr. KOHL, Mr. NELSON
of Nebraska, Mr. GRASSLEY, Mr. LUGAR, Mr. BOND, Mr. BROWNBACK, Mrs. FEINSTEIN,
Mr. AKAKA, Mr. BINGAMAN, Mr. BAUCUS, Mr. BURNS, Mr. CRAIG, Mr. ENZI, Mr.
THOMAS, Mrs. LINCOLN, Mr. EDWARDS, Mr. HOLLINGS, Mr. HELMS, Mrs. CLINTON,
Mr. CRAPO, Ms. MIKULSKI, Mr. LEAHY, Mr. FITZGERALD, Mr. WYDEN, Mr. ROCKEFELLER,
Mr. ALLARD, and Ms. STABENOW) introduced the following bill; which was
read twice and referred to the Committee on Agriculture, Nutrition, and
Forestry
A BILL
To provide the citizens
of the United States and Congress with a report on coordinated actions
by Federal agencies to prevent the introduction of foot and mouth disease
and bovine spongiform encephalopathy into the United States and other information
to assess the economic and public health impacts associated with the potential
threats presented by those diseases.
Be it enacted by the
Senate and House of Representatives of the United States of America in
Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as
the `Animal Disease Risk Assessment, Prevention, and Control Act of 2001'.
SEC. 2. FINDINGS AND PURPOSE.
(a) FINDINGS- Congress finds
that--
(1) it is in the interest
of the United States to maintain healthy livestock herds;
(2) managing the risks of
foot and mouth disease, bovine spongiform encephalopathy, and related diseases
in the United States may require billions of dollars for remedial activities
by consumers, producers, and distributors of meat and blood products;
(3) the potential introduction
of those diseases into the United States would cause devastating financial
losses to--
(A) the agriculture industry
and other economic sectors; and
(B) United States trade
in the affected animals and animal products;
(4) foot and mouth disease
is a severe and highly contagious viral infection affecting cattle, deer,
goats, sheep, swine, and other animals;
(5) the most effective means
of eradicating foot and mouth disease is by the slaughter of affected animals;
(6) while foot and mouth
disease was eradicated in the United States in 1929, the virus could be
reintroduced by--
(A) a single infected animal,
an animal product, or a person carrying the virus;
(B) an act of terrorism;
or
(7) once introduced, foot
and mouth disease can spread quickly through--
(A) exposure to aerosols
from infected animals;
(B) direct contact with
infected animals; and
(C) contact with contaminated
feed, equipment, or humans harboring the virus or carrying the virus on
their clothing;
(8) foot and mouth disease
is endemic to more than 2/3 of the world and is considered to be widespread
in parts of Africa, Asia, Europe, and South America;
(9) foot and mouth disease
occurs in over 7 different serotypes and 60 subtypes;
(10) as foot and mouth disease
outbreaks have occurred, the United States has banned the importation of
live ruminants and swine and many animal products from countries affected
by foot and mouth disease;
(11) recently, the United
States has implemented bans in response to outbreaks in Argentina, the
European Union, and Taiwan;
(12) although United States
exclusion programs have been successful at keeping foot and mouth disease
out of the United States since 1929, recent outbreaks in Argentina, the
European Union, and Taiwan are placing an unprecedented strain on our animal
health system;
(13) bovine spongiform encephalopathy
is a transmissible, neuro-degenerative disease found in cattle;
(14) in cattle with bovine
spongiform encephalopathy, the active agent is found primarily in the brain
and spinal cord and has not been found in commonly consumed beef products;
(15) bovine spongiform encephalopathy
is thought to have an incubation period of several years but is ultimately
fatal to cattle within weeks of onset of the active disease;
(16) bovine spongiform encephalopathy
was first widely found in 1986 in cattle in the United Kingdom;
(17) bovine spongiform encephalopathy-carrying
cattle have been found in cattle in Belgium, Denmark, France, Germany,
Ireland, Italy, Liechtenstein, Luxembourg, the Netherlands, Portugal, Spain,
and Switzerland;
(18) cattle infected with
bovine spongiform encephalopathy originating from the United Kingdom have
been found and intercepted in Canada;
(19) since 1989, the Secretary
of Agriculture has prohibited the importation of live grazing animals from
countries where bovine spongiform encephalopathy has been found in cattle;
(20) other products derived
from grazing animals, such as blood meal, bonemeal, fat, fetal bovine serum,
glands, meat-and-bone meal, and offal, are prohibited from entry, except
under special conditions or under permits issued by the Secretary of Agriculture
for scientific or research purposes;
(21) on December 12, 1997,
the Secretary of Agriculture extended those restrictions to include all
countries in Europe because of concerns about widespread risk factors and
inadequate surveillance for bovine spongiform encephalopathy;
(22) on December 7, 2000,
the Secretary of Agriculture prohibited all imports of rendered animal
protein products from Europe;
(23) Creutzfeldt-Jacob disease
is a human spongiform encephalopathy;
(24) on March 20, 1996,
the Spongiform Encephalopathy Advisory Committee of the United Kingdom
announced the identification of 10 cases of a new variant of Creutzfeldt-Jacob
disease;
(25) all 10 patients developed
onsets of the disease in 1994 or 1995;
(26) scientific experts
(including scientists at the Department of Agriculture, the Department
of Health and Human Services, and the World Health Organization) are studying
the possible link (including potential routes of transmission) between
bovine spongiform encephalopathy and variant Creutzfeldt-Jacob disease;
(27) from October 1996 to
December 2000, 87 cases of variant Creutzfeldt-Jacob disease have been
reported in the United Kingdom, 3 cases in France, and 1 case in Ireland;
and
(28) to reduce the risk
of human spongiform encephalopathies in the United States, the Commissioner
of Food and Drugs has--
(A) banned individuals who
lived in Great Britain for at least 180 days since 1980 from donating blood
in the United States; and
(B) established regulations
that prohibit the feeding of most animal-derived proteins to grazing animals.
(b) PURPOSE- The purpose
of this Act is to provide the people of the United States and Congress
with information concerning--
(1) actions by Federal agencies
to prevent foot and mouth disease, bovine spongiform encephalopathy, and
related diseases;
(2) the sufficiency of legislative
authority to prevent or control foot and mouth disease, bovine spongiform
encephalopathy, and related diseases in the United States;
(3) the economic impacts
associated with the potential introduction of foot and mouth disease, bovine
spongiform encephalopathy, and related diseases into the United States;
and
(4) the risks to public
health from possible links between bovine spongiform encephalopathy and
other spongiform encephalopathies to human illnesses.
SEC. 3. REPORT TO CONGRESS.
(1) IN GENERAL- Not later
than 30 days after the date of enactment of this Act, the Secretary of
Agriculture shall submit to the Committees and Subcommittees described
in paragraph (2) a preliminary report concerning--
(A) coordinated interagency
activities to assess, prevent, and control the spread of foot and mouth
disease and bovine spongiform encephalopathy in the United States;
(B) sources of information
from the Federal Government available to the public on foot and mouth disease
and bovine spongiform encephalopathy; and
(C) any immediate needs
for additional legislative authority, appropriations, or product bans to
prevent the introduction of foot and mouth disease or bovine spongiform
encephalopathy into the United States.
(2) SUBMISSION OF REPORT
TO CONGRESS- The Secretary shall submit the preliminary report to--
(A) the Committee on Agriculture
of the House of Representatives;
(B) the Committee on Agriculture,
Nutrition, and Forestry of the Senate;
(C) the Subcommittee on
Agriculture, Rural Development, and Related Agencies of the Committee on
Appropriations of the Senate; and
(D) the Subcommittee on
Agriculture, Rural Development, Food and Drug Administration, and Related
Agencies of the Committee on Appropriations of the House of Representatives.
(1) IN GENERAL- Not later
than 180 days after the date of enactment of this Act, the Secretary of
Agriculture shall submit to the Committees and Subcommittees described
in subsection (a)(2) a final report that--
(A) discusses the economic
impacts associated with the potential introduction of foot and mouth disease,
bovine spongiform encephalopathy, and related diseases into the United
States;
(B) discusses the potential
risks to public and animal health from foot and mouth disease, bovine spongiform
encephalopathy, and related diseases; and
(C) provides recommendations
to protect the health of animal herds and citizens of the United States
from those risks including, if necessary, recommendations for additional
legislation, appropriations, or product bans.
(2) CONTENTS- The report
shall contain--
(A) an assessment of the
risks to the public presented by the potential presence of foot and mouth
disease, bovine spongiform encephalopathy, and related diseases in domestic
and imported livestock, livestock and animal products, wildlife, and blood
products;
(B) recommendations to reduce
and manage the risks of foot and mouth disease, bovine spongiform encephalopathy,
and related diseases;
(C) any plans of the Secretary
to identify, prevent, and control foot and mouth disease, bovine spongiform
encephalopathy, and related diseases in domestic and imported livestock,
livestock products, wildlife, and blood products;
(D) a description of the
incidence and prevalence of foot and mouth disease, bovine
spongiform encephalopathy, variant
Creutzfeldt-Jacob disease, and related diseases in other countries;
(E) a description and an
analysis of the effectiveness of the measures taken to assess, prevent,
and control the risks of foot and mouth disease, bovine spongiform encephalopathy,
variant Creutzfeldt-Jacob disease, and related diseases in other countries;
(F) a description and an
analysis of the effectiveness of the measures that the public, private,
and nonprofit sectors have taken to assess, prevent, and control the risk
of foot and mouth disease, bovine spongiform encephalopathy, and related
diseases in the United States, including controls of ports of entry and
other conveyances;
(G) a description of the
measures taken to prevent and control the risk of bovine spongiform encephalopathy
and variant Creutzfeldt-Jacob disease transmission through blood collection
and transfusion;
(H) a description of any
measures (including any planning or managerial initiatives such as interagency,
intergovernmental, international, and public-private sector partnerships)
that any Federal agency plans to initiate or continue to assess, prevent,
and control the spread of foot and mouth disease, bovine spongiform encephalopathy,
variant Creutzfeldt-Jacob disease, and related diseases in the United States
and other countries;
(I) plans by Federal agencies
(including the Centers for Disease Control and Prevention)--
(i) to monitor the incidence
and prevalence of the transmission of foot and mouth disease, bovine spongiform
encephalopathy, variant Creutzfeldt-Jacob disease, and related diseases
in the United States; and
(ii) to assess the effectiveness
of efforts to prevent and control the spread of foot and mouth disease,
bovine spongiform encephalopathy, variant Creutzfeldt-Jacob disease, and
related diseases in the United States;
(J) plans by Federal agencies
(including the Agricultural Research Service, the Cooperative State Research,
Education, and Extension Service, and the National Institutes of Health)
to carry out, in partnership with the private sector--
(i) research programs into
the causes and mechanism of transmission of foot and mouth disease and
bovine spongiform encephalopathy; and
(ii) diagnostic tools and
preventive and therapeutic agents for foot and mouth disease, bovine spongiform
encephalopathy, variant Creutzfeldt-Jacob disease, and related diseases;
(K) plans for providing
appropriate compensation for affected animals in the event of the introduction
of foot and mouth disease, bovine spongiform encephalopathy, or related
diseases into the United States; and
(L) recommendations to Congress
for legislation that will improve efforts to assess, prevent, or control
the transmission of foot and mouth disease, bovine spongiform encephalopathy,
variant Creutzfeldt-Jacob disease, and related diseases in the United States
and in other countries.
(1) PRELIMINARY REPORT-
In preparing the preliminary report under subsection (a), the Secretary
shall consult with--
(A) the Secretary of the
Treasury
(B) the Secretary of Commerce;
(C) the Secretary of State;
(D) the Secretary of Health
and Human Services;
(E) the Secretary of Defense;
(F) the United States Trade
Representative;
(G) the Director of the
Federal Emergency Management Agency; and
(H) representatives of other
appropriate Federal agencies;
(2) FINAL REPORT- In preparing
the final report under subsection (b), the Secretary shall consult with--
(A) the individuals listed
in paragraph (1);
(B) private and nonprofit
sector experts in infectious disease, research, prevention, and control;
(C) international, State,
and local governmental animal health officials;
(D) private, nonprofit,
and public sector livestock experts;
(E) representatives of blood
collection and distribution entities; and
(F) representatives of consumer
and patient organizations and other interested members of the public.
|